Stereotaxis, Inc.

NYSEAM:STXS Stock Report

Market Cap: US$176.2m

Stereotaxis Valuation

Is STXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of STXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate STXS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate STXS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STXS?

Key metric: As STXS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for STXS. This is calculated by dividing STXS's market cap by their current revenue.
What is STXS's PS Ratio?
PS Ratio7x
SalesUS$25.14m
Market CapUS$176.24m

Price to Sales Ratio vs Peers

How does STXS's PS Ratio compare to its peers?

The above table shows the PS ratio for STXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
BDMD Baird Medical Investment Holdings
9.6xn/aUS$316.6m
NVRO Nevro
0.4x3.2%US$171.2m
ZJYL Jin Medical International
7.2xn/aUS$144.0m
KEQU Kewaunee Scientific
0.9xn/aUS$178.1m
STXS Stereotaxis
7x49.7%US$176.2m

Price-To-Sales vs Peers: STXS is expensive based on its Price-To-Sales Ratio (7x) compared to the peer average (4.5x).

Price to Sales Ratio vs Industry

How does STXS's PS Ratio compare vs other companies in the US Medical Equipment Industry?

48 CompaniesPrice / SalesEstimated GrowthMarket Cap
VREX Varex Imaging
0.7x2.3%US$557.44m
INGN Inogen
0.8x4.4%US$249.38m
ARAY Accuray
0.5x5.5%US$225.27m
NVRO Nevro
0.4x3.2%US$171.25m
STXS 7.0xIndustry Avg. 3.5xNo. of Companies48PS03.26.49.612.816+
48 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: STXS is expensive based on its Price-To-Sales Ratio (7x) compared to the US Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is STXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STXS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7x
Fair PS Ratio7.5x

Price-To-Sales vs Fair Ratio: STXS is good value based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (7.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst STXS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.08
US$4.50
+116.3%
11.1%US$5.00US$4.00n/a4
Jan ’26US$2.28
US$4.50
+97.4%
11.1%US$5.00US$4.00n/a4
Dec ’25US$2.39
US$4.50
+88.3%
11.1%US$5.00US$4.00n/a4
Nov ’25US$1.94
US$4.50
+132.0%
11.1%US$5.00US$4.00n/a4
Oct ’25US$1.91
US$4.50
+135.6%
11.1%US$5.00US$4.00n/a4
Sep ’25US$2.29
US$4.50
+96.5%
11.1%US$5.00US$4.00n/a4
Aug ’25US$1.88
US$4.50
+139.4%
11.1%US$5.00US$4.00n/a4
Jul ’25US$1.77
US$4.50
+154.2%
11.1%US$5.00US$4.00n/a4
Jun ’25US$1.93
US$4.50
+133.2%
11.1%US$5.00US$4.00n/a4
May ’25US$2.41
US$4.50
+86.7%
11.1%US$5.00US$4.00n/a4
Apr ’25US$2.58
US$4.60
+78.3%
10.7%US$5.00US$4.00n/a5
Mar ’25US$2.70
US$4.40
+63.0%
18.2%US$5.00US$3.00n/a5
Feb ’25US$2.16
US$4.40
+103.7%
18.2%US$5.00US$3.00n/a5
Jan ’25US$1.75
US$4.25
+142.9%
19.5%US$5.00US$3.00US$2.284
Dec ’24US$1.77
US$4.25
+140.1%
19.5%US$5.00US$3.00US$2.394
Nov ’24US$1.50
US$4.90
+226.7%
13.5%US$6.00US$4.00US$1.945
Oct ’24US$1.58
US$4.90
+210.1%
13.5%US$6.00US$4.00US$1.915
Sep ’24US$1.82
US$4.90
+169.2%
13.5%US$6.00US$4.00US$2.295
Aug ’24US$1.49
US$4.90
+228.9%
13.5%US$6.00US$4.00US$1.885
Jul ’24US$1.53
US$4.90
+220.3%
13.5%US$6.00US$4.00US$1.775
Jun ’24US$2.27
US$5.10
+124.7%
13.0%US$6.00US$4.00US$1.935
May ’24US$1.76
US$5.30
+201.1%
18.5%US$7.00US$4.00US$2.415
Apr ’24US$2.04
US$5.42
+165.5%
17.2%US$7.00US$4.00US$2.586
Mar ’24US$2.57
US$5.83
+127.0%
11.8%US$7.00US$5.00US$2.706
Feb ’24US$2.14
US$6.63
+209.6%
32.0%US$12.00US$5.00US$2.168
Jan ’24US$2.07
US$6.63
+220.0%
32.0%US$12.00US$5.00US$1.758
Analyst Price Target
Consensus Narrative from 4 Analysts
US$4.50
Fair Value
53.8% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 16:54
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Stereotaxis, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charley JonesBarrington Research Associates, Inc.
Neil ChatterjiB. Riley Securities, Inc.
Tao LevyCollins Stewart LLC